CTLA4 and neoplasm: Furthermore, given the importance of immunological checkpoints in tumour development, we studied the relationship between IRS and various checkpoints (Figure 9D), and the results showed that patients with a low IRS had lower levels of CTLA4 and PD‐1 (Figure 9E), implying that the immunotherapy response may differ between the two IRS patient groups.